These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21406545)

  • 21. The double polymethylmethacrylate filter (DELETE system) in the removal of light chains in chronic dialysis patients with multiple myeloma.
    Santoro A; Grazia M; Mancini E
    Blood Purif; 2013; 35 Suppl 2():5-13. PubMed ID: 23676829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.
    Tate JR; Mollee P; Dimeski G; Carter AC; Gill D
    Clin Chim Acta; 2007 Feb; 376(1-2):30-6. PubMed ID: 16945362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
    Cserti C; Haspel R; Stowell C; Dzik W
    Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of immunological assessment in patients with acute kidney injury and possible myeloma.
    Lachmann HJ; Wassef NL
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of serum free light chains predict renal recovery.
    Hutchison CA
    Ann Hematol; 2010 Jun; 89(6):627-8. PubMed ID: 19784650
    [No Abstract]   [Full Text] [Related]  

  • 27. Renal failure in myeloma: relationship with isoelectric point of immunoglobulin light chains.
    Melcion C; Mougenot B; Baudouin B; Ronco P; Moulonguet-Doleris L; Vanhille P; Beaufils M; Morel-Maroger L; Verroust P; Richet G
    Clin Nephrol; 1984 Sep; 22(3):138-43. PubMed ID: 6435919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.
    Davenport A; Merlini G
    Nephrol Dial Transplant; 2012 Oct; 27(10):3713-8. PubMed ID: 23114897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal treatment of cast nephropathy.
    Gakhar B; Kobrin S; Berns JS
    Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proposed reference material for human free immunoglobulin light chain measurement.
    Nakano T; Miyazaki S; Shinoda Y; Inoue I; Katayama S; Komoda T; Nagata A
    J Immunoassay Immunochem; 2006; 27(2):129-37. PubMed ID: 16711251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe renal failure in multiple myeloma.
    Cosio FG; Pence TV; Shapiro FL; Kjellstrand CM
    Proc Clin Dial Transplant Forum; 1980; 10():177-80. PubMed ID: 6810342
    [No Abstract]   [Full Text] [Related]  

  • 32. [Progress in the management of multiple myeloma introduced by serum free light chain measurement].
    Shimazaki C
    Rinsho Ketsueki; 2010 Oct; 51(10):1491-8. PubMed ID: 20962483
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
    Bidet A; Marit G; Bérard AM
    Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Survival of myeloma patients treated with dialysis].
    Martín Reyes G; Valera A; Frutos MA; Ramos B; Ordóñez V; López de Novales E
    Nefrologia; 2003; 23(2):131-6. PubMed ID: 12778877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
    Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcemia as the presenting feature of multiple myeloma.
    Costa DB; Shin B; Cooper DL
    Am J Hematol; 2004 Nov; 77(3):277-81. PubMed ID: 15495248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
    Shaheen SP; Levinson SS
    Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
    Hutchison CA; Cockwell P; Stringer S; Bradwell A; Cook M; Gertz MA; Dispenzieri A; Winters JL; Kumar S; Rajkumar SV; Kyle RA; Leung N
    J Am Soc Nephrol; 2011 Jun; 22(6):1129-36. PubMed ID: 21511832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
    Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
    BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
    Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
    J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.